-
1
-
-
48249125791
-
Malignant gliomas in adults
-
Wen PY, Kesari S. Malignant gliomas in adults. N. Engl. J. Med. 359(5), 492-507 (2008).
-
(2008)
N. Engl. J. Med.
, vol.359
, Issue.5
, pp. 492-507
-
-
Wen, P.Y.1
Kesari, S.2
-
2
-
-
20044366163
-
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
-
Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352(10), 987-996 (2005).
-
(2005)
N. Engl. J. Med.
, vol.352
, Issue.10
, pp. 987-996
-
-
Stupp, R.1
Mason, W.P.2
Van Den Bent, M.J.3
-
3
-
-
65349121788
-
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year analysis of the EORTC-NCIC trial
-
Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10(5), 459-466 (2009).
-
(2009)
Lancet Oncol.
, vol.10
, Issue.5
, pp. 459-466
-
-
Stupp, R.1
Hegi, M.E.2
Mason, W.P.3
-
4
-
-
78650271417
-
Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004
-
doi:10.1093/neuonc/noq030 Epub ahead of print
-
Bauchet L, Mathieu-Daude H, Fabbro-Peray P et al. Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004. Neuro Oncol. doi:10.1093/neuonc/noq030 (2010) (Epub ahead of print).
-
(2010)
Neuro Oncol.
-
-
Bauchet, L.1
Mathieu-Daude, H.2
Fabbro-Peray, P.3
-
5
-
-
78651313326
-
Population-based incidence and survival of central nervous system (CNS) malignancies in Girona (Spain) 1994-2005
-
Fuentes-Raspall R, Vilardell L, Perez-Bueno F et al. Population-based incidence and survival of central nervous system (CNS) malignancies in Girona (Spain) 1994-2005. J. Neurooncol. 101(1), 117-123 (2011).
-
(2011)
J. Neurooncol.
, vol.101
, Issue.1
, pp. 117-123
-
-
Fuentes-Raspall, R.1
Vilardell, L.2
Perez-Bueno, F.3
-
6
-
-
77955002912
-
Patterns of care and survival in a retrospective analysis of 1059 patients with glioblastoma multiforme treated between 2002 and 2007: A multicenter study by the Central Nervous System Study Group of Airo (Italian Association of Radiation Oncology)
-
Scoccianti S, Magrini SM, Ricardi U et al. Patterns of care and survival in a retrospective analysis of 1059 patients with glioblastoma multiforme treated between 2002 and 2007: a multicenter study by the Central Nervous System Study Group of Airo (Italian Association of Radiation Oncology). Neurosurgery 67(2), 446-458 (2010).
-
(2010)
Neurosurgery
, vol.67
, Issue.2
, pp. 446-458
-
-
Scoccianti, S.1
Magrini, S.M.2
Ricardi, U.3
-
7
-
-
84873081348
-
Improved survival time trends for glioblastoma using the SEER 17 population-based registries
-
Koshy M, Vilano JL, Dolecek TA et al. Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J. Clin. Oncol. 29(Suppl.), 2013 (2011).
-
(2011)
J. Clin. Oncol.
, vol.29
, Issue.SUPPL.
, pp. 2013
-
-
Koshy, M.1
Vilano, J.L.2
Dolecek, T.A.3
-
8
-
-
84873085001
-
A population-based study of glioblastoma multiforme (GBM) in the new stupp paradigm: Have we improved outcome?
-
Abstract
-
Lwin Z, MacFadden D, Al-Zahrani A et al. A population-based study of glioblastoma multiforme (GBM) in the new stupp paradigm: have we improved outcome? J. Clin. Oncol. 29(Suppl.), 2012 (2011) (Abstract).
-
(2011)
J. Clin. Oncol.
, vol.29
, Issue.SUPPL.
, pp. 2012
-
-
Lwin, Z.1
MacFadden, D.2
Al-Zahrani, A.3
-
9
-
-
84873093693
-
Real-life survival in unselected adult glioblastoma patients: A population-based study
-
Abstract
-
Preusser M, Woehrer A, Zielonke N et al. Real-life survival in unselected adult glioblastoma patients: A population-based study. J. Clin. Oncol. 29(Suppl.), 2014 (2011) (Abstract).
-
(2011)
J. Clin. Oncol.
, vol.29
, Issue.SUPPL.
, pp. 2014
-
-
Preusser, M.1
Woehrer, A.2
Zielonke, N.3
-
10
-
-
55849130720
-
Novel anti-angiogenic therapies for malignant gliomas
-
Norden AD, Drappatz J, Wen PY. Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol. 7(12), 1152-1160 (2008).
-
(2008)
Lancet Neurol.
, vol.7
, Issue.12
, pp. 1152-1160
-
-
Norden, A.D.1
Drappatz, J.2
Wen, P.Y.3
-
11
-
-
49749124673
-
Clinical pharmacokinetics of bevacizumab in patients with solid tumors
-
Lu JF, Bruno R, Eppler S, Novotnv W, Lum B, Gaudreault J. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother. Pharmacol. 62(5), 779-786 (2008).
-
(2008)
Cancer Chemother. Pharmacol.
, vol.62
, Issue.5
, pp. 779-786
-
-
Lu, J.F.1
Bruno, R.2
Eppler, S.3
Novotnv, W.4
Lum, B.5
Gaudreault, J.6
-
12
-
-
32944482137
-
Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma
-
Abstract
-
Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro Oncol. 7(369) (2005) (Abstract).
-
(2005)
Neuro Oncol.
, vol.7
, Issue.369
-
-
Stark-Vance, V.1
-
13
-
-
84873084779
-
Bevacizumab (B) with irinotecan (I) in recurrent glioblastoma (Gbm): A national retrospective cohort of the ANOCEF (Association des Neuro-Oncologues D'Expression Francaise) Group
-
Abstract
-
Taillibert S, Hoang-Xuan K, Barrie M et al. Bevacizumab (B) with irinotecan (I) in recurrent glioblastoma (Gbm): a national retrospective cohort of the ANOCEF (Association des Neuro-Oncologues D'Expression Francaise) Group. Neuro Oncol. 12, 52-53 (2010) (Abstract).
-
(2010)
Neuro Oncol.
, vol.12
, pp. 52-53
-
-
Taillibert, S.1
Hoang-Xuan, K.2
Barrie, M.3
-
14
-
-
77953872335
-
Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme
-
Francesconi AB, Dupre S, Matos M et al. Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme. J. Clin. Neurosci. 17(8), 970-974 (2010).
-
(2010)
J. Clin. Neurosci.
, vol.17
, Issue.8
, pp. 970-974
-
-
Francesconi, A.B.1
Dupre, S.2
Matos, M.3
-
15
-
-
84873085777
-
Efficacy, safety and pattern of relapse of bevacizumab versus chemotherapy for recurrent glioblastoma multiforme: A McGill University study
-
Abstract
-
Sehebjam S, Ang C, Guiot M et al. Efficacy, safety and pattern of relapse of bevacizumab versus chemotherapy for recurrent glioblastoma multiforme: a McGill University study. Ann. Oncol. 21(Suppl. 8), 1059P (2010) (Abstract).
-
(2010)
Ann. Oncol.
, vol.21
, Issue.SUPPL. 8
, pp. 1059
-
-
Sehebjam, S.1
Ang, C.2
Guiot, M.3
-
16
-
-
75049085069
-
Salvage therapy with single-agent bevacizumab for recurrent glioblastoma
-
Chamberlain MC, Johnston SK. Salvage therapy with single-agent bevacizumab for recurrent glioblastoma. J. Neurooncol. 96(2), 259-269 (2010).
-
(2010)
J. Neurooncol.
, vol.96
, Issue.2
, pp. 259-269
-
-
Chamberlain, M.C.1
Johnston, S.K.2
-
17
-
-
79956135686
-
Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials
-
Hofer S, Elandt K, Greil R et al. Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. Acta Oncol. 50(5), 630-635 (2011).
-
(2011)
Acta Oncol.
, vol.50
, Issue.5
, pp. 630-635
-
-
Hofer, S.1
Elandt, K.2
Greil, R.3
-
18
-
-
65249185501
-
Bevacizumab and chemotherapy for recurrent glioblastoma: A single-institution experience
-
Nghiemphu PL, Liu W, Lee Y et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 72(14), 1217-1222 (2009).
-
(2009)
Neurology
, vol.72
, Issue.14
, pp. 1217-1222
-
-
Nghiemphu, P.L.1
Liu, W.2
Lee, Y.3
-
19
-
-
58149090856
-
Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours
-
Poulsen HS, Grunnet K, Sorensen M et al. Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. Acta Oncol. 48(1), 52-58 (2009).
-
(2009)
Acta Oncol.
, vol.48
, Issue.1
, pp. 52-58
-
-
Poulsen, H.S.1
Grunnet, K.2
Sorensen, M.3
-
20
-
-
58149456505
-
Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan
-
Zuniga RM, Torcuator R, Jain R et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J. Neurooncol. 91(3), 329-336 (2009).
-
(2009)
J. Neurooncol.
, vol.91
, Issue.3
, pp. 329-336
-
-
Zuniga, R.M.1
Torcuator, R.2
Jain, R.3
-
21
-
-
79958217698
-
Recurrent spinal cord glioblastoma: Salvage therapy with bevacizumab
-
Chamberlain MC, Johnston SK. Recurrent spinal cord glioblastoma: salvage therapy with bevacizumab. J. Neurooncol. 102(3), 427-432 (2011).
-
(2011)
J. Neurooncol.
, vol.102
, Issue.3
, pp. 427-432
-
-
Chamberlain, M.C.1
Johnston, S.K.2
-
22
-
-
36049037819
-
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
-
Vredenburgh JJ, Desjardins A, Herndon JE et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol. 25(30), 4722-4729 (2007).
-
(2007)
J. Clin. Oncol.
, vol.25
, Issue.30
, pp. 4722-4729
-
-
Vredenburgh, J.J.1
Desjardins, A.2
Herndon, J.E.3
-
23
-
-
71649094684
-
Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: A Phase II study
-
Reardon DA, Desjardins A, Vredenburgh JJ et al. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a Phase II study. Br. J. Cancer 101(12), 1986-1994 (2009).
-
(2009)
Br. J. Cancer
, vol.101
, Issue.12
, pp. 1986-1994
-
-
Reardon, D.A.1
Desjardins, A.2
Vredenburgh, J.J.3
-
24
-
-
80053142607
-
Phase II trial of bevacizumab with fotemustine in recurrent glioblastoma: Final results of a multicenter study of AINO (Italian Association of Neuro-oncology)
-
Abstract
-
Soffietti R, Trevisan E, Ruda R et al. Phase II trial of bevacizumab with fotemustine in recurrent glioblastoma: final results of a multicenter study of AINO (Italian Association of Neuro-oncology). J. Clin. Oncol. 29(Suppl.), 2027 (2011) (Abstract).
-
(2011)
J. Clin. Oncol.
, vol.29
, Issue.SUPPL.
, pp. 2027
-
-
Soffietti, R.1
Trevisan, E.2
Ruda, R.3
-
25
-
-
84951208522
-
Bevacizumab and fotemustine as salvage therapy in recurrent glioblastoma: A Phase II multicenter Italian study
-
Abstract
-
Trevisan E, Ruda R, Picco E et al. Bevacizumab and fotemustine as salvage therapy in recurrent glioblastoma: a Phase II multicenter Italian study. Neuro Oncol. 12(iii), P117 (2010) (Abstract).
-
(2010)
Neuro Oncol.
, vol.12
, Issue.3
-
-
Trevisan, E.1
Ruda, R.2
Picco, E.3
-
26
-
-
83455209534
-
Bevacizumab in combination with irinotecan or temozolomide in recurrent glioblastoma: Efficacy and safety results from a pilot study
-
Abstract
-
Kobyakov G, Absalyamova O, Amanov R. Bevacizumab in combination with irinotecan or temozolomide in recurrent glioblastoma: efficacy and safety results from a pilot study. Neuro Oncol. 12, 54 (2010) (Abstract).
-
(2010)
Neuro Oncol.
, vol.12
, pp. 54
-
-
Kobyakov, G.1
Absalyamova, O.2
Amanov, R.3
-
27
-
-
84951013721
-
Updated results of a Phase II trial of bevacizumab and irinotecan in relapsed high grade glioma
-
Abstract
-
Keyrouz VR, Elias EF, Chahine GY, Comair YG, Dimassi H, Kamar FG. Updated results of a Phase II trial of bevacizumab and irinotecan in relapsed high grade glioma. Neuro Oncol. 12(iii), P108 (2010) (Abstract).
-
(2010)
Neuro Oncol.
, vol.12
, Issue.3
-
-
Keyrouz, V.R.1
Elias, E.F.2
Chahine, G.Y.3
Comair, Y.G.4
Dimassi, H.5
Kamar, F.G.6
-
28
-
-
77955242817
-
Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma
-
Verhoeff JJC, Lavini C, van Linde ME et al. Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma. Ann. Oncol. 21(8), 1723-1727 (2010).
-
(2010)
Ann. Oncol.
, vol.21
, Issue.8
, pp. 1723-1727
-
-
Verhoeff, J.J.C.1
Lavini, C.2
Van Linde, M.E.3
-
29
-
-
59949083263
-
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma
-
Kreisl TN, Kim L, Moore K et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 27(5), 740-745 (2009).
-
(2009)
J. Clin. Oncol.
, vol.27
, Issue.5
, pp. 740-745
-
-
Kreisl, T.N.1
Kim, L.2
Moore, K.3
-
30
-
-
78449274656
-
A Phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas
-
Raizer JJ, Grimm S, Chamberlain MC et al. A Phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer 116(22), 5297-5305 (2010).
-
(2010)
Cancer
, vol.116
, Issue.22
, pp. 5297-5305
-
-
Raizer, J.J.1
Grimm, S.2
Chamberlain, M.C.3
-
31
-
-
80052609763
-
Long-term survival from the initial trial of bevacizumab and irinotecan
-
Abstract
-
Desjardins A, Vredenburgh JJ, Reardon DA et al. Long-term survival from the initial trial of bevacizumab and irinotecan. J. Clin. Oncol. 28(15s), 2045 (2010) (Abstract).
-
(2010)
J. Clin. Oncol.
, vol.28
, Issue.15
, pp. 2045
-
-
Desjardins, A.1
Vredenburgh, J.J.2
Reardon, D.A.3
-
32
-
-
84873096007
-
Results of treatment pediatric recurrent high grade glioma with combination of bevacizumab and irinotecan
-
Abstract
-
Geludkova OG, Borodina ID, Melikian AG et al. Results of treatment pediatric recurrent high grade glioma with combination of bevacizumab and irinotecan. Neuro Oncol. 12(iii), P131 (2010) (Abstract).
-
(2010)
Neuro Oncol.
, vol.12
, Issue.3
-
-
Geludkova, O.G.1
Borodina, I.D.2
Melikian, A.G.3
-
33
-
-
77954578108
-
Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: A pediatric brain tumor consortium study
-
Gururangan S, Chi SN, Poussaint TY et al. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a pediatric brain tumor consortium study. J. Clin. Oncol. 28(18), 3069-3075 (2010).
-
(2010)
J. Clin. Oncol.
, vol.28
, Issue.18
, pp. 3069-3075
-
-
Gururangan, S.1
Chi, S.N.2
Poussaint, T.Y.3
-
34
-
-
70350461699
-
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma
-
Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27(28), 4733-4740 (2009).
-
(2009)
J. Clin. Oncol.
, vol.27
, Issue.28
, pp. 4733-4740
-
-
Friedman, H.S.1
Prados, M.D.2
Wen, P.Y.3
-
35
-
-
77956666382
-
Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study
-
Abstract
-
Cloughesy TF, Vredenburgh JJ, Day B, Das A, Friedland HS. Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study. J. Clin. Oncol. 28(15s), 2008 (2010) (Abstract).
-
(2010)
J. Clin. Oncol.
, vol.28
, Issue.15 S
, pp. 2008
-
-
Cloughesy, T.F.1
Vredenburgh, J.J.2
Day, B.3
Das, A.4
Friedland, H.S.5
-
36
-
-
79951632471
-
Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab
-
Prados M, Cloughesy T, Samant M et al. Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 13(1), 143-151 (2011).
-
(2011)
Neuro Oncol.
, vol.13
, Issue.1
, pp. 143-151
-
-
Prados, M.1
Cloughesy, T.2
Samant, M.3
-
37
-
-
78650990754
-
Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study
-
Vredenburgh JJ, Cloughesy T, Samant M et al. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist 15(12), 1329-1334 (2010).
-
(2010)
Oncologist
, vol.15
, Issue.12
, pp. 1329-1334
-
-
Vredenburgh, J.J.1
Cloughesy, T.2
Samant, M.3
-
38
-
-
79952140602
-
Rtog 0625: A randomized Phase II trial of bevacizumab with either irinotecan (Cpt) or dose-dense temozolomide (Tmz) in recurrent glioblastoma (Gbm)
-
Abstract
-
Gilbert MR, Wang MH, Aldape K et al. Rtog 0625: a randomized Phase II trial of bevacizumab with either irinotecan (Cpt) or dose-dense temozolomide (Tmz) in recurrent glioblastoma (Gbm). Neuro Oncol. 12, 39 (2010) (Abstract).
-
(2010)
Neuro Oncol.
, vol.12
, pp. 39
-
-
Gilbert, M.R.1
Wang, M.H.2
Aldape, K.3
-
39
-
-
84873093206
-
Toxicity of combined bevacizumab-lomustine treatment in patients with recurrent glioblastoma (Gbm): Report from a randomized Phase II study
-
Abstract
-
van den Bent M, Taal W, Sleijfer S et al. Toxicity of combined bevacizumab-lomustine treatment in patients with recurrent glioblastoma (Gbm): report from a randomized Phase II study. Neuro Oncol. 12, 42 (2010) (Abstract).
-
(2010)
Neuro Oncol.
, vol.12
, pp. 42
-
-
Van Den Bent, M.1
Taal, W.2
Sleijfer, S.3
-
40
-
-
83455167756
-
Bevacizumab for recurrent glioblastoma multiforme: A meta-analysis
-
Abstract
-
Wong ET, Gautam S, Malchow C, Lun M, Pan E, Brem S. Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis. Ann. Neurol. 68(4), S61-S62 (2010) (Abstract).
-
(2010)
Ann. Neurol.
, vol.68
, Issue.4
-
-
Wong, E.T.1
Gautam, S.2
Malchow, C.3
Lun, M.4
Pan, E.5
Brem, S.6
-
41
-
-
83055181490
-
Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients
-
doi:10.1007/s11060-011-0642-1 Epub ahead of print
-
Norden AD, Bartolomeo J, Tanaka S et al. Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients. J. Neurooncol. doi:10.1007/s11060-011-0642-1 (2011) (Epub ahead of print).
-
(2011)
J. Neurooncol.
-
-
Norden, A.D.1
Bartolomeo, J.2
Tanaka, S.3
-
42
-
-
79957976065
-
Impact of bevacizumab chemotherapy on craniotomy wound healing
-
Clark AJ, Butowski NA, Chang SM et al. Impact of bevacizumab chemotherapy on craniotomy wound healing. J. Neurosurg. 114(6), 1609-1616 (2011).
-
(2011)
J. Neurosurg.
, vol.114
, Issue.6
, pp. 1609-1616
-
-
Clark, A.J.1
Butowski, N.A.2
Chang, S.M.3
-
43
-
-
77954991899
-
Optic neuropathy in patients with glioblastoma receiving bevacizumab
-
Chamberlain MC, Raizer J. Optic neuropathy in patients with glioblastoma receiving bevacizumab. Neurology 75(3), 289-290 (2010).
-
(2010)
Neurology
, vol.75
, Issue.3
, pp. 289-290
-
-
Chamberlain, M.C.1
Raizer, J.2
-
44
-
-
73349106835
-
Optic neuropathy in patients with glioblastoma receiving bevacizumab
-
Sherman JH, Aregawi DG, Lai A et al. Optic neuropathy in patients with glioblastoma receiving bevacizumab. Neurology 73(22), 1924-1926 (2009).
-
(2009)
Neurology
, vol.73
, Issue.22
, pp. 1924-1926
-
-
Sherman, J.H.1
Aregawi, D.G.2
Lai, A.3
-
45
-
-
77954720781
-
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma
-
Batchelor TT, Duda DG, di Tomaso E et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J. Clin. Oncol. 28(17), 2817-2823 (2010).
-
(2010)
J. Clin. Oncol.
, vol.28
, Issue.17
, pp. 2817-2823
-
-
Batchelor, T.T.1
Duda, D.G.2
Di Tomaso, E.3
-
46
-
-
79951957939
-
A Phase III randomized study comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, with lomustine alone in recurrent glioblastoma patients
-
Abstract
-
Batchelor TT, Mulholland P, Neyns B, et al. A Phase III randomized study comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, with lomustine alone in recurrent glioblastoma patients. Ann. Oncol. 21(Suppl. 8), LBA7 (2010) (Abstract).
-
(2010)
Ann. Oncol.
, vol.21
, Issue.SUPPL. 8
-
-
Batchelor, T.T.1
Mulholland, P.2
Neyns, B.3
-
47
-
-
77949891455
-
Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma
-
Wick W, Puduvalli VK, Chamberlain MC et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J. Clin. Oncol. 28(7), 1168-1174 (2010).
-
(2010)
J. Clin. Oncol.
, vol.28
, Issue.7
, pp. 1168-1174
-
-
Wick, W.1
Puduvalli, V.K.2
Chamberlain, M.C.3
-
48
-
-
34447285771
-
Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium Phase i and II clinical trials
-
Carson KA, Grossman SA, Fisher JD, Shaw EG. Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium Phase I and II clinical trials. J. Clin. Oncol. 25(18), 2601-2606 (2007).
-
(2007)
J. Clin. Oncol.
, vol.25
, Issue.18
, pp. 2601-2606
-
-
Carson, K.A.1
Grossman, S.A.2
Fisher, J.D.3
Shaw, E.G.4
-
49
-
-
84873076918
-
Bevacizumab-based therapy recurrent malignant glioma: Correlation between serum VEGF and response to treatment
-
Pace A, Conti L, Russillo M et al. Bevacizumab-based therapy recurrent malignant glioma: correlation between serum VEGF and response to treatment. Neuro Oncol. 12, 33-34 (2010).
-
(2010)
Neuro Oncol.
, vol.12
, pp. 33-34
-
-
Pace, A.1
Conti, L.2
Russillo, M.3
-
50
-
-
84856008240
-
The role of the development of hypertension or proteinuria in predicting outcome with the use of bevacizumab for patients with glioblastoma multiforme (GBM)
-
Abstract
-
Nangia CS, Wang D, Scarpace L, Schultz L, Khanshour A, Mikkelsen T. The role of the development of hypertension or proteinuria in predicting outcome with the use of bevacizumab for patients with glioblastoma multiforme (GBM). J. Clin. Oncol. 29(Suppl.), 2021 (2011) (Abstract).
-
(2011)
J. Clin. Oncol.
, vol.29
, Issue.SUPPL.
, pp. 2021
-
-
Nangia, C.S.1
Wang, D.2
Scarpace, L.3
Schultz, L.4
Khanshour, A.5
Mikkelsen, T.6
-
51
-
-
77955653792
-
Diffusion restriction as a predictor of response in recurrent glioblastoma patients receiving bevacizumab
-
Abstract
-
Wu J, Gilbert MR, de Groot JF, Yung WA, Puduvalli VK. Diffusion restriction as a predictor of response in recurrent glioblastoma patients receiving bevacizumab. J. Clin. Oncol. 28(15s), 2024 (2010) (Abstract).
-
(2010)
J. Clin. Oncol.
, vol.28
, Issue.15
, pp. 2024
-
-
Wu, J.1
Gilbert, M.R.2
De Groot, J.F.3
Yung, W.A.4
Puduvalli, V.K.5
-
52
-
-
80052001722
-
Isolated diffusion restriction precedes the development of enhancing tumor in a subset of patients with glioblastoma
-
Gupta A, Young RJ, Karimi S, et al. Isolated diffusion restriction precedes the development of enhancing tumor in a subset of patients with glioblastoma. AJNR Am. J. Neuroradiol. 32(7), 1301-1306 (2011).
-
(2011)
AJNR Am. J. Neuroradiol.
, vol.32
, Issue.7
, pp. 1301-1306
-
-
Gupta, A.1
Young, R.J.2
Karimi, S.3
-
53
-
-
77949911509
-
Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab
-
Gerstner ER, Frosch MP, Batchelor TT. Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. J. Clin. Oncol. 28(6), e91-e93 (2010).
-
(2010)
J. Clin. Oncol.
, vol.28
, Issue.6
-
-
Gerstner, E.R.1
Frosch, M.P.2
Batchelor, T.T.3
-
54
-
-
36048955738
-
Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: A pilot study
-
Chen W, Delaloye S, Silverman DHS et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J. Clin. Oncol. 25, 4714-4721 (2007).
-
(2007)
J. Clin. Oncol.
, vol.25
, pp. 4714-4721
-
-
Chen, W.1
Delaloye, S.2
Silverman, D.H.S.3
-
55
-
-
67649092660
-
Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab
-
Quant EC, Norden AD, Drappatz J et al. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol. 11(5), 550-555 (2009).
-
(2009)
Neuro Oncol.
, vol.11
, Issue.5
, pp. 550-555
-
-
Quant, E.C.1
Norden, A.D.2
Drappatz, J.3
-
56
-
-
70350142397
-
Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma
-
Iwamoto FM, Abrey LE, Beal K et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 73(15), 1200-1206 (2009).
-
(2009)
Neurology
, vol.73
, Issue.15
, pp. 1200-1206
-
-
Iwamoto, F.M.1
Abrey, L.E.2
Beal, K.3
-
57
-
-
77956061453
-
Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma
-
Zuniga RM, Torcuator R, Jain R et al. Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma. J. Neurooncol. 99(2), 237-242 (2010).
-
(2010)
J. Neurooncol.
, vol.99
, Issue.2
, pp. 237-242
-
-
Zuniga, R.M.1
Torcuator, R.2
Jain, R.3
-
58
-
-
79959812904
-
Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy
-
Reardon DA, Desjardins A, Peters K et al. Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. J. Neurooncol. 103(2), 371-379 (2011).
-
(2011)
J. Neurooncol.
, vol.103
, Issue.2
, pp. 371-379
-
-
Reardon, D.A.1
Desjardins, A.2
Peters, K.3
-
59
-
-
80053145837
-
Meta-analysis of five consecutive recurrent glioblastoma (GBM) trials
-
Abstract
-
Reardon DA, Vredenburgh JJ, Desjardins A et al. Meta-analysis of five consecutive recurrent glioblastoma (GBM) trials. J. Clin. Oncol. 29(Suppl.), 2030 (2011) (Abstract).
-
(2011)
J. Clin. Oncol.
, vol.29
, Issue.SUPPL.
, pp. 2030
-
-
Reardon, D.A.1
Vredenburgh, J.J.2
Desjardins, A.3
-
60
-
-
79953282797
-
Bevacizumab does not increase the risk of remote relapse in malignant glioma
-
Wick A, Dörner N, Schäfer N et al. Bevacizumab does not increase the risk of remote relapse in malignant glioma. Ann. Neurol. 69(3), 586-592 (2011).
-
(2011)
Ann. Neurol.
, vol.69
, Issue.3
, pp. 586-592
-
-
Wick, A.1
Dörner, N.2
Schäfer, N.3
-
61
-
-
80053601205
-
Safety results from a prospective study of concurrent radiosurgery and bevacizumab for recurrent malignant glioma
-
Abstract
-
Cuneo KC, Cabrera AR, Sampson JH et al. Safety results from a prospective study of concurrent radiosurgery and bevacizumab for recurrent malignant glioma. J. Clin. Oncol. 29(Suppl.), 2082 (2011) (Abstract).
-
(2011)
J. Clin. Oncol.
, vol.29
, Issue.SUPPL.
, pp. 2082
-
-
Cuneo, K.C.1
Cabrera, A.R.2
Sampson, J.H.3
-
62
-
-
68649114787
-
Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas
-
Gutin PH, Iwamoto FM, Beal K et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int. J. Radiat. Oncol. Biol. Phys. 75(1), 156-163 (2009).
-
(2009)
Int. J. Radiat. Oncol. Biol. Phys.
, vol.75
, Issue.1
, pp. 156-163
-
-
Gutin, P.H.1
Iwamoto, F.M.2
Beal, K.3
-
63
-
-
78650102866
-
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma
-
Sathornsumetee S, Desjardins A, Vredenburgh JJ et al. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol. 12(12), 1300-1310 (2010).
-
(2010)
Neuro Oncol.
, vol.12
, Issue.12
, pp. 1300-1310
-
-
Sathornsumetee, S.1
Desjardins, A.2
Vredenburgh, J.J.3
-
64
-
-
77954748580
-
Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: A Phase II trial
-
Hasselbalch B, Lassen U, Hansen S et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a Phase II trial. Neuro Oncol. 12(5), 508-516 (2010).
-
(2010)
Neuro Oncol.
, vol.12
, Issue.5
, pp. 508-516
-
-
Hasselbalch, B.1
Lassen, U.2
Hansen, S.3
-
65
-
-
84873089729
-
Phase II trial of enzastaurin (Enz) with bevacizumab (Bv) in adults with recurrent glioblastoma (Gem)
-
Abstract
-
Moustakas A, Iwamoto FM, Kreisl TN et al. Phase II trial of enzastaurin (Enz) with bevacizumab (Bv) in adults with recurrent glioblastoma (Gem). Neuro Oncol. 12, 37 (2010) (Abstract).
-
(2010)
Neuro Oncol.
, vol.12
, pp. 37
-
-
Moustakas, A.1
Iwamoto, F.M.2
Kreisl, T.N.3
-
66
-
-
84866721138
-
Phase II study of bevacizumab and temsirolimus in patients with progressive glioblastoma multiforme after prior bevacizumab treatment
-
Gaziel TB, Soerensen M, Hasselbalch B, Poulsen HS, Lassen U. Phase II study of bevacizumab and temsirolimus in patients with progressive glioblastoma multiforme after prior bevacizumab treatment. Neuro Oncol. 12, 40 (2010).
-
(2010)
Neuro Oncol.
, vol.12
, pp. 40
-
-
Gaziel, T.B.1
Soerensen, M.2
Hasselbalch, B.3
Poulsen, H.S.4
Lassen, U.5
-
67
-
-
83455209525
-
Phase II clinical trial of bortezomib and bevacizumab combination in recurrent glioblastoma
-
Abstract
-
Bota DA, Eroglu Z, Reardon DA et al. Phase II clinical trial of bortezomib and bevacizumab combination in recurrent glioblastoma. J. Clin. Oncol. 29(Suppl.), 2056 (2011) (Abstract).
-
(2011)
J. Clin. Oncol.
, vol.29
, Issue.SUPPL.
, pp. 2056
-
-
Bota, D.A.1
Eroglu, Z.2
Reardon, D.A.3
-
68
-
-
84873077741
-
NCCTG Phase II trial of bevacizumab in combination with sorafenib in recurrent GBM
-
Galanis E, Jaeckle KA, Anderson SK et al. NCCTG Phase II trial of bevacizumab in combination with sorafenib in recurrent GBM. J. Clin. Oncol. 28(15s), 2018 (2010).
-
(2010)
J. Clin. Oncol.
, vol.28
, Issue.15
, pp. 2018
-
-
Galanis, E.1
Jaeckle, K.A.2
Anderson, S.K.3
-
69
-
-
83455209522
-
A Phase i trial of LBH589 and bevacizumab for recurrent high-grade glioma (HGG)
-
Abstract
-
Drappatz J, Raizer JJ, Schiff D et al. A Phase I trial of LBH589 and bevacizumab for recurrent high-grade glioma (HGG). J. Clin. Oncol. 29(Suppl.), 2050 (2011) (Abstract).
-
(2011)
J. Clin. Oncol.
, vol.29
, Issue.SUPPL.
, pp. 2050
-
-
Drappatz, J.1
Raizer, J.J.2
Schiff, D.3
-
70
-
-
84873096930
-
Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma
-
Abstract
-
Lou E, Reardon DA, Peters K et al. Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma. J. Clin. Oncol. 29(Suppl.), 2055 (2011) (Abstract).
-
(2011)
J. Clin. Oncol.
, vol.29
, Issue.SUPPL.
, pp. 2055
-
-
Lou, E.1
Reardon, D.A.2
Peters, K.3
-
71
-
-
80053141888
-
Randomized multicenter Phase II trial of irinotecan and bevacizumab as neoadjuvant and adjuvant to temozolomide-based chemoradiation versus chemoradiation for unresectable glioblastoma: Interim results of the TEMAVIR study from the ANOCEF group
-
Abstract
-
Chauffert B, Feuvet L, Bonnetain F et al. Randomized multicenter Phase II trial of irinotecan and bevacizumab as neoadjuvant and adjuvant to temozolomide-based chemoradiation versus chemoradiation for unresectable glioblastoma: interim results of the TEMAVIR study from the ANOCEF group. J. Clin. Oncol. 29(Suppl.), 2029 (2011) (Abstract).
-
(2011)
J. Clin. Oncol.
, vol.29
, Issue.SUPPL.
, pp. 2029
-
-
Chauffert, B.1
Feuvet, L.2
Bonnetain, F.3
-
72
-
-
78751705500
-
First-line therapy with bevacizumab and irinotecan versus bevacizumab and temozolomide and delayed concomitant radiotherapy in newly diagnosed primary glioblastoma multiforme: Early results from a randomized Phase II study
-
Abstract
-
Hofland KF, Poulsen HS, Sorensen MP et al. First-line therapy with bevacizumab and irinotecan versus bevacizumab and temozolomide and delayed concomitant radiotherapy in newly diagnosed primary glioblastoma multiforme: early results from a randomized Phase II study. Neuro Oncol. 11(5), 620 (2009) (Abstract).
-
(2009)
Neuro Oncol.
, vol.11
, Issue.5
, pp. 620
-
-
Hofland, K.F.1
Poulsen, H.S.2
Sorensen, M.P.3
-
73
-
-
84873086814
-
The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide and irinotecan for newly diagnosed glioblastoma
-
Vredenburgh JJ, Desjardins A, Reardon DA et al. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide and irinotecan for newly diagnosed glioblastoma. Clin.Cancer Res. 69(3), 586-592 (2011).
-
(2011)
Clin. Cancer Res.
, vol.69
, Issue.3
, pp. 586-592
-
-
Vredenburgh, J.J.1
Desjardins, A.2
Reardon, D.A.3
-
74
-
-
79951984402
-
Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme
-
Lai A, Tran A, Nghiemphu PL et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J. Clin. Oncol. 29(2), 142-148 (2011).
-
(2011)
J. Clin. Oncol.
, vol.29
, Issue.2
, pp. 142-148
-
-
Lai, A.1
Tran, A.2
Nghiemphu, P.L.3
-
75
-
-
80053146368
-
Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM)
-
Abstract
-
Omuro AM, Beal K, Karimi S et al. Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM). J. Clin. Oncol. 29(Suppl.), 2028 (2011) (Abstract).
-
(2011)
J. Clin. Oncol.
, vol.29
, Issue.SUPPL.
, pp. 2028
-
-
Omuro, A.M.1
Beal, K.2
Karimi, S.3
-
76
-
-
79958210803
-
AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme
-
Chinot OL, de La Motte Rouge T, Moore N et al. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv. Ther. 28(4), 334-340 (2011).
-
(2011)
Adv. Ther.
, vol.28
, Issue.4
, pp. 334-340
-
-
Chinot, O.L.1
De La Motte Rouge, T.2
Moore, N.3
-
77
-
-
79960606592
-
Phase II trial of radiation therapy/temozolomide/bevacizumab followed by bevacizumab/everolimus in the first-line treatment of glioblastoma multiforme (GBM)
-
Abstract
-
Shih KC, Spikel DR, Burris HA III, Brown RH, Shepard GC, Hainsworth JD. Phase II trial of radiation therapy/temozolomide/bevacizumab followed by bevacizumab/everolimus in the first-line treatment of glioblastoma multiforme (GBM). J. Clin. Oncol. 28(15s), 2075 (2010) (Abstract).
-
(2010)
J. Clin. Oncol.
, vol.28
, Issue.15
, pp. 2075
-
-
Shih, K.C.1
Spikel, D.R.2
Burris Iii, H.A.3
Brown, R.H.4
Shepard, G.C.5
Hainsworth, J.D.6
-
78
-
-
75449088610
-
FDA Drug Approval Summary: Bevacizumab (Avastin®) as treatment of recurrent glioblastoma multiforme
-
Cohen MH, Shen YL, Keegan P, Pazdur R. FDA Drug Approval Summary: bevacizumab (Avastin®) as treatment of recurrent glioblastoma multiforme. Oncologist 14(11), 1131-1138 (2009).
-
(2009)
Oncologist
, vol.14
, Issue.11
, pp. 1131-1138
-
-
Cohen, M.H.1
Shen, Y.L.2
Keegan, P.3
Pazdur, R.4
-
79
-
-
79958206587
-
Approval denied by the European Medicines Agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: A good idea or a grave error?
-
Balana C, Etxaniz O, Buges C, Martinez A. Approval denied by the European Medicines Agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: a good idea or a grave error? Clin. Transl. Oncol. 13(3), 209-210 (2011).
-
(2011)
Clin. Transl. Oncol.
, vol.13
, Issue.3
, pp. 209-210
-
-
Balana, C.1
Etxaniz, O.2
Buges, C.3
Martinez, A.4
-
81
-
-
84873097055
-
-
European Medicines Agency Accessed 24 November 2011)
-
European Medicines Agency. Product information Avastin. www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/ 000582/WC500029271.pdf (Accessed 24 November 2011)
-
Product Information Avastin
-
-
-
82
-
-
76949086699
-
-
National Cancer Institute Accessed 11 July 2011
-
National Cancer Institute. Clinical Trials Homepage. www.cancer.gov/ clinicaltrials (Accessed 11 July 2011)
-
Clinical Trials Homepage
-
-
-
83
-
-
84873090562
-
-
US FDA Department of Health and Human Services Accessed 30 June 2011
-
US FDA. Department of Health and Human Services. www.accessdata.fda.gov/ drugsatfda-docs/appletter/2009/125085s0169ltr.pdf (Accessed 30 June 2011)
-
-
-
-
84
-
-
84873095213
-
-
European Medicines Agency Accessed 24 November 2011
-
European Medicines Agency. Avastin: refusal registration glioblastoma. www.ema.europa.eu/docs/en-GB/document-library/EPAR-Assessment-Report-Variation/ human/000582/WC500075000.pdf (Accessed 24 November 2011)
-
Avastin: Refusal Registration Glioblastoma
-
-
|